We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Mechanical Heart Valves Better Than Biological Ones

By HospiMedica International staff writers
Posted on 25 Nov 2015
A new study suggests that mechanical valve prostheses last longer and have a better survival record than biological valve prostheses.

Researchers at Karolinska Institutet (Solna, Sweden) and Karolinska University Hospital (Stockholm, Sweden) conducted a study among 4,545 patients (50–69 years of age) who underwent aortic valve replacement (AVR) with bioprosthetic or mechanical valves in Sweden between 1997 and 2013; in all, 60% of the patients received mechanical valves and 40% received bioprostheses. More...
The patients were distributed to 1,099 propensity score-matched patient pairs to investigate long-term all-cause mortality outcomes.

The results showed that 16% of the mechanical valve group and 20% of the bioprosthetic group died during a mean follow-up period of 6.6 years. Long-term survival was higher in the mechanical than in the bioprosthetic group when evaluated at five, 10, and 15 years, with an overall hazard ration of 1.34. There was no difference in stroke outcomes, but patients who received bioprostheses had a higher risk of aortic valve reoperation and a lower risk of major bleeding. The study was published on November 12, 2015, in European Heart Journal.

“Biological valve prostheses have been used more and more in young patients in recent years, partly because these patients don't have to take blood thinners,” said lead author Natalie Glaser, MD, a PhD student at the Karolinska Institutet department of molecular medicine and surgery, and a physician at the Karolinska University Hospital department of cardiothoracic surgery. “Our research shows that mechanical valve prostheses should be the preferred option for young patients.”

“We show that patients who had received a mechanical prosthesis had better survival rates than those who had received a biological prosthesis,” added senior author cardiac surgeon Ulrik Sartipy, MD, of the Karolinska University Hospital department of cardiothoracic surgery. “Our results are important since the trend in Sweden and abroad in recent years has been towards a greater use of biological valve prostheses in relatively young patients, which has no backing in clinical therapy guidelines.”

While mechanical valves are the longest lasting type of replacement valve, patients will usually require blood thinners to stop clots from forming, as they can lodge in valve flaps or hinges which can cause malfunction or form emboli. Bioprosthetic tissue valves can last 10–20 years, but usually do not require long-term use of medication. On the other hand, in a young person a bioprosthetic valve will usually need replacement later in life.

Related Links:

Karolinska Institutet
Karolinska University Hospital



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Syringes
Prefilled Saline Flush Syringes
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.